breast cancer - HER2-positive | |
la/mBC - HER2 positive - 2nd Line (L2) | |
lapatinib plus trastuzumab | EGF104900 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -